Skip to main contentAI and Advanced
/
SYNGENE · NSEBSE SENSEX74,583.84+0.33%BSE |
NIFTY 5023,322.4+0.45%NSE |
NIFTY BANK56,496.3+0.36%NSE |
NIFTY IT28,976.65-0.38%NSE |
NIFTY AUTO27,148.25+0.95%NSE |
NIFTY FMCG45,838.85+0.61%NSE |
NIFTY PHARMA26,369.95+0.86%NSE |
NIFTY 50022,675.25+0.64%NSE |
SY
NSE · Equity shares · Biotechnology & Drugs-1.40 · -0.37%
Syngene International SYNGENE
NSE:INR 378.7
BSE:INR 379.15
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SYNGENE
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 380.1
Day rangeINR 374.2 — INR 382.4
52-week rangeINR 374.2 — INR 709.3
Volume2.68 L
Market cap16,091.36
P/E79.96
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)3,738.7
Net Income (INR Cr)316.7
Rev Growth (5 Year %)11.35
EPS Growth (5 Year %)-4.89
P/E Ratio79.96
EPS9.39
Research path: Interpret Syngene International's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SYNGENESyngene International1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 7,054.7 | 6,795.9 | 6,151.6 |
| Accumulated Depreciation Total | -2,782.3 | -2,402.8 | -2,086.5 |
| Cash Equivalents | 28 | 85.5 | Not available |
| Other Liabilities Total | 264.8 | 263.9 | 284.5 |
| Accrued Expenses | 26.3 | 0.3 | Not available |
| Common Stock Total | 402.9 | 402.5 | 402 |
| Other Equity Total | -101.5 | 94.6 | 109.2 |
| Other Current Assets Total | 6.9 | 53.2 | 69.4 |
| Prepaid Expenses | 37 | 25.8 | 16.4 |
| Total Assets | 7,054.7 | 6,795.9 | 6,151.6 |
| Current Portof LT Debt/Capital Leases | 50.5 | 152 | 90.1 |
| Additional Paid-In Capital | 270.6 | 243.7 | 216.7 |
| Cash | 200.6 | 281.6 | 85.7 |
| Total Equity | 4,839.1 | 4,726.8 | 4,257.8 |
| Long Term Investments | 591.9 | 72.3 | 76 |
| Retained Earnings(Accumulated Deficit) | 4,272.4 | 3,991.3 | 3,535.2 |
| Treasury Stock-Common | -5.3 | -5.3 | -5.3 |
| Total Common Shares Outstanding | 40.18 | 40.14 | 40.08 |
| Property/Plant/Equipment Total-Gross | 6,752.8 | 6,406 | 5,703.9 |
| Tangible Book Valueper Share Common Eq | 119.35 | 117 | 105.5 |
| Total Liabilities | 2,215.6 | 2,069.1 | 1,893.8 |
| Total Debt | 458.4 | 577.9 | 555.2 |
| Short Term Investments | 1,060.5 | 1,030.4 | 991 |
| Cashand Short Term Investments | 1,289.1 | 1,397.5 | 1,076.7 |
| Total Receivables Net | 668.5 | 655.3 | 558 |
| Notes Payable/Short Term Debt | 9.4 | 17.1 | 0 |
| Accounts Receivable-Trade Net | 531 | 540.6 | 458.2 |
| Property/Plant/Equipment Total-Net | 3,970.3 | 4,003.2 | 3,617.5 |
| Total Current Liabilities | 1,552.3 | 1,396.4 | 1,144.2 |
| Total Inventory | 141.3 | 155.5 | 238.5 |
| Accounts Payable | 347.5 | 352 | 255.5 |
| Other Currentliabilities Total | 1,118.6 | 875 | 798.6 |
| Total Long Term Debt | 398.5 | 408.8 | 465.1 |
| Intangibles Net | 43.9 | 30.3 | 29.5 |
| Other Long Term Assets Total | 172.7 | 250 | 268.2 |
| Note Receivable-Long Term | 133.1 | 152.8 | 201.4 |
| Total Current Assets | 2,142.8 | 2,287.3 | 1,959 |
| Capital Lease Obligations | 398.5 | 408.8 | 365.1 |
| Long Term Debt | Not available | 0 | 100 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %-12.48
Margins
Operating Margin 12m10.14
Operating Margin 5y Avg16.51
Net Profit Margin 12m6.14
Net Profit Margin 5y13.1
Yield
Dividend Yield %0.31
Valuation
Price to Sale Ratio4.30
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk34.99
Analyst consensus
ConsensusBuy
Consensus score2.38
Analyst opinions8
Strong Sell count1
Sell count0
Hold count2
Buy count3
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 52.59%
- FII
- 11.82%
- MF
- 25.78%
- Other
- 9.81%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Buy or sell: Vaishali Parekh recommends two intraday stocks to buy today — 16 March 2026Market news · 16 Mar 2026, 7:01 am
Buy or sell stocks for 16 March: Vaishali Parekh recommends two intraday stocks to buy today — Syngene International, Tata Consumer Products
Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — 16 March 2026Market news · 14 Mar 2026, 1:07 pm
Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — Syngene International, Muthoot Finance, and Tata Consumer Products
Buy or sell: Vaishali Parekh recommends three intraday stocks to buy today — 19 February 2026Market news · 19 Feb 2026, 9:18 am
Buy or sell: Vaishali Parekh recommends three intraday stocks to buy today — Syngene International, Carborundum Universal, and Hyundai Motor India
Mirae Asset Mutual Fund trims stake in Syngene International to 2.95%. Details hereMarket news · 4 Sept 2025, 5:17 pm
Mirae Asset Mutual Fund has slightly decreased its stake in Syngene International to 2.95% by selling 667,386 shares. Syngene, which reported a 59% rise in Q1 FY26 profit, remains under stock pressure despite a significant long-term gain since March 2020.
Syngene International share price gains 2% despite weak Indian stock markets: Should you buy or sell the stock?Market news · 25 Jul 2025, 12:22 pm
Stock Market Today: Syngene International share price gained more than 2% in the intraday trades on Friday despite weak Indian stock markets. Should you buy or sell?
Technical Picks: Nagaraj Shetti of HDFC Sec suggests these two stocks to buy or sell this week amid stock market fallMarket news · 13 Jan 2025, 2:15 pm
Technical Picks: Nagaraj Shetti of HDFC Securities recommends these two stocks this week - Crisil Ltd, and Syngene International Ltd.
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.2500 per share(12.5%)Final Dividend
- annual General MeetingPOM
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Syngene International
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Syngene International Limited is an India-based integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The Company's services include discovery, development, manufacturing, SynVent Integrated Drug discovery, dedicated centers, and Center for Advanced Protein Studies (CAPS). Its discovery services span the entire spectrum of early-stage research from target identification to delivery of drug candidates for further development. It offers preclinical development, active pharmaceutical ingredient and drug product development for both small molecules and biologics. It has capabilities for current Good Manufacturing Practices (cGMP) manufacturing from benchtop volume to commercial scale. SynVent is its drug discovery platform for enabling fully integrated therapeutic drug discovery and development across small molecules, new modalities and biologics.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SYNGENE
- BSE Code
- 539268
Questions
Stock FAQ
What is the symbol and ISIN of Syngene International?
Syngene International has the symbol SYNGENE and ISIN - INE398R01022.
What is the current price of Syngene International?
Syngene International is currently trading at INR 378.70.
What are the year high and year low of Syngene International?
Syngene International has a year high of INR 709.30 and a year low of INR 374.20.
What is the market capitalization of Syngene International?
Syngene International has a market capitalization of INR 16,091.36 crore.
What is the P/E ratio of Syngene International?
Syngene International has a P/E ratio of 79.96.
What is the dividend yield of Syngene International?
Syngene International has a dividend yield of 0.31%.
How is the financial performance of Syngene International based on revenue, net income, and EPS?
Syngene International has revenue of INR 3,738.70 crore, net income of INR 316.70 crore, and EPS of INR 6.74.
What is the book value of Syngene International?
Syngene International has a book value of NA.
What is the debt-to-equity ratio of Syngene International?
Syngene International has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Syngene International?
Syngene International has a price-to-book ratio of NA and a price-to-sales ratio of 4.30.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.